COMMUNIQUÉS West-GlobeNewswire

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
05/10/2026
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
05/10/2026
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily [...]
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
05/10/2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort [...]
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
05/10/2026
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing Milestone [...]
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
05/10/2026
Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 05, [...]
Cannara Expands International Supply Agreement with Curaleaf
05/10/2026
MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara étend son entente d’approvisionnement international avec Curaleaf
05/10/2026
MONTRÉAL, 05 oct. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), un producteur verticalement intégré de [...]
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
05/10/2026
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in [...]
Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
05/10/2026
Multi-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular gate medicines for Lilly targets BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Gate [...]
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
05/10/2026
Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research Company planning NDA [...]
4DMT to Host Investor Day on October 21, 2026
05/10/2026
Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; [...]
Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
05/10/2026
Quarter included presentation at H.C. Wainwright Global Investment Conference, strategic partnership with Alpmed, new regulatory registrations, and continued physician training NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE [...]
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
05/10/2026
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for [...]
MAPS and International Alliance of Psychedelic Therapy Practitioners Announce Partnership to Advance Training for Psychedelic-Assisted Therapy
05/10/2026
Collaboration will increase access to practitioner education in the United States and internationally Partnership brings experienced psychedelic-assisted therapy practitioners together to guide the next generation of [...]
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
05/10/2026
The BB-301 pivotal trial remains on track to begin in mid-2027 Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional [...]
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
05/10/2026
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial [...]
Your Postal Code Shouldn’t Determine Your COPD Care. In Canada, It Still Does.
05/10/2026
Lung Health Foundation’s new Canadian COPD Performance Index finds significant shortfalls in COPD care across the country, driven by missing data, workforce shortages and no national strategy. Here’s where your region [...]
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
05/10/2026
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 ® (PCV20) and/or Capvaxive ® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31 [...]
Upgrade of revenue and operating profit guidance
05/10/2026
ANNOUNCEMENT NO. 317 5 October 2026 ChemoMetec maintained its positive momentum in the first quarter of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with the NC-203 being a [...]

Pages